ARTICLE | Company News
Eisai, Eurofarma Laboratorios deal
October 10, 2016 7:00 AM UTC
Eisai’s Morphotek Inc. subsidiary granted Eurofarma exclusive, Latin American rights to develop and commercialize farletuzumab, a humanized IgG1 antibody targeting the folate receptor 1 ( FOLR1; FR-alpha). The product is in a Phase II trial to treat platinum-sensitive ovarian cancer in first relapse in patients with low levels of mucin 16 ( MUC16; CA125). ...